Investigates the impact of protocol development on the appropriate use of hydroxocobalamin in treating cyanide toxicity from inhalation injuries.
Conducted a pre-post analysis
Developed criteria for hydroxocobalamin usage
Identified risk factors for cyanide toxicity
Improved identification of patients at risk for cyanide toxicity
Enhanced stewardship of hydroxocobalamin usage
Increased awareness around inhalation injury management
Abstract
Identification of patients with risk factors for inhalation injury with cyanide toxicity is key. Development of criteria for use ensures judicious stewardship of this antidote.